Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection

Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection

The increased prevalence of pulmonary methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infection in patients living with cystic fibrosis (CF) is concerning due to a correlation with reduced life expectancy and lack of available treatment options. RV94 is a next generation lipogl...

Full description

Bibliographic Details
Main Authors: Donna M. Konicek, Adam J. Plaunt, Sachin Gharse, Sasha J. Rose, Arielle Dorfman, Amruta Sabnis, Thomas Baker, Helena Gauani, Donald Chun, Zhili Li, Walter R. Perkins, David Cipolla, Vladimir S. Malinin
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Pharmaceutics
Subjects:
DPI
antibiotics
cystic fibrosis
MRSA
lipoglycopeptide
inhalation
Online Access:https://www.mdpi.com/1999-4923/15/9/2250

Internet

https://www.mdpi.com/1999-4923/15/9/2250

Similar Items